Search Results - "Maser, Tyler"
-
1
Nrf2-Dependent and -Independent Effects of tert -Butylhydroquinone, CDDO-Im, and H 2 O 2 in Human Jurkat T Cells as Determined by CRISPR/Cas9 Gene Editing
Published in The Journal of pharmacology and experimental therapeutics (01-05-2017)“…Nuclear factor erythroid 2-related factor 2 (Nrf2) is a stress-activated transcription factor activated by stimuli such as electrophilic compounds and other…”
Get more information
Journal Article -
2
The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma
Published in Cancer medicine (Malden, MA) (01-11-2020)“…Background Neuroblastoma (NB) is the most common extracranial solid tumor in infants and children, with amplification of the oncogene MYCN being a hallmark of…”
Get full text
Journal Article -
3
Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma
Published in Cancer medicine (Malden, MA) (01-06-2017)“…Catechol‐O‐methyltransferase (COMT) is an enzyme that inactivates dopamine and other catecholamines by O‐methylation. Tolcapone, a drug commonly used in the…”
Get full text
Journal Article -
4
Abstract 3190: DFMO preferentially drives cancer stem cells in neuroblastoma towards senescence
Published in Cancer research (Chicago, Ill.) (01-07-2018)“…Abstract Background: High-risk neuroblastoma (HRNB) is an aggressive form of the most common extracranial solid tumor cancer in children, often characterized…”
Get full text
Journal Article -
5
DIPG-29. DFMO AND PANOBINOSTAT TARGET LIN28 AND HDAC IN DIPG DECREASING CELL VIABILITY
Published in Neuro-oncology (Charlottesville, Va.) (23-04-2019)“…Abstract BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is an aggressive pediatric cancer with a poor prognosis of < 10% overall survival at 2 years from…”
Get full text
Journal Article -
6
Abstract 3191: The MDM2 inhibitor CGM097 synergizes with the BET inhibitor OTX015 to induce cell death in neuroblastoma cells
Published in Cancer research (Chicago, Ill.) (01-07-2018)“…Abstract Background: Neuroblastoma (NB) is the most common extracranial solid tumor in infants and children, with amplification of the oncogene MYCN being a…”
Get full text
Journal Article -
7
The Nrf2 activators tBHQ and CDDO-Im have both Nrf2-dependent and – independent effects on human Jurkat T cell activation, as determined by CRISPR-Cas9 gene editing
Published in The Journal of immunology (1950) (01-05-2017)“…Abstract Nuclear factor erythroid 2-related factor 2 (Nrf2) is a stress activated transcription factor, activated by such stimuli as reactive oxygen and…”
Get full text
Journal Article -
8
Determination of the Effects of Nrf2 upon the Early Events of Jurkat T Cell Activation by Use of CRISPR‐CAS9 Mediated Mutation
Published in The FASEB journal (01-04-2015)“…Abstract only Nuclear factor erythroid 2‐related factor 2 (Nrf2) is a transcription factor activated by cell stresses, such as reactive oxygen species and…”
Get full text
Journal Article -
9
ETMR-18. TARGETING Lin28 IN ETMR WITH ODC1 INHIBITOR DFMO
Published in Neuro-oncology (Charlottesville, Va.) (04-12-2020)“…Abstract Embryonal tumor with multilayered rosettes (ETMR), is an aggressive brain tumor primarily occurring in young patients (<4 years of age) and…”
Get full text
Journal Article -
10
The Nrf2 activator, tBHQ, inhibits IL-2 production by human T cells in a largely Nrf2-independent manner
Published in The Journal of immunology (1950) (01-05-2016)“…Abstract Nrf2 is a transcription factor that is activated by cell stress, such as oxidative insult and exposure to xenobiotics. Upon activation, Nrf2…”
Get full text
Journal Article